Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,637 shares of the medical research company’s stock after selling 2,042 shares during the quarter. Van ECK Associates Corp owned about 0.11% of Charles River Laboratories International worth $15,075,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in CRL. LPL Financial LLC increased its position in Charles River Laboratories International by 14.5% during the third quarter. LPL Financial LLC now owns 38,349 shares of the medical research company’s stock worth $7,498,000 after buying an additional 4,856 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Charles River Laboratories International by 8.8% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,604 shares of the medical research company’s stock worth $706,000 after purchasing an additional 292 shares during the last quarter. Bank of Nova Scotia boosted its position in Charles River Laboratories International by 24.2% during the third quarter. Bank of Nova Scotia now owns 2,634 shares of the medical research company’s stock worth $516,000 after purchasing an additional 513 shares during the period. Schonfeld Strategic Advisors LLC grew its holdings in Charles River Laboratories International by 222.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 12,004 shares of the medical research company’s stock valued at $2,353,000 after purchasing an additional 8,285 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of Charles River Laboratories International by 187.2% in the third quarter. Lazard Asset Management LLC now owns 52,037 shares of the medical research company’s stock worth $10,197,000 after buying an additional 33,918 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Stock Down 1.5 %

Shares of NYSE:CRL traded down $2.96 during midday trading on Friday, hitting $198.46. The stock had a trading volume of 230,692 shares, compared to its average volume of 536,829. The business’s 50-day simple moving average is $217.52 and its 200-day simple moving average is $231.91. Charles River Laboratories International, Inc. has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a market cap of $10.22 billion, a P/E ratio of 23.70, a PEG ratio of 1.91 and a beta of 1.38. The company has a quick ratio of 1.37, a current ratio of 1.75 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, topping analysts’ consensus estimates of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the topic of several research analyst reports. Mizuho assumed coverage on shares of Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price on the stock. Argus restated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. Barclays started coverage on Charles River Laboratories International in a research report on Friday, June 28th. They issued an “equal weight” rating and a $230.00 price objective for the company. Robert W. Baird lowered their price objective on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Finally, StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, June 14th. Eight research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $254.50.

Insider Buying and Selling

In other news, EVP Joseph W. Laplume sold 1,304 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).